Phase IIa proof-of-concept, open-label study of extended-release metadoxine in adults with attention-deficit hyperactivity disorder

Trial Profile

Phase IIa proof-of-concept, open-label study of extended-release metadoxine in adults with attention-deficit hyperactivity disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs Metadoxine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Alcobra
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top